The federal Project Grant award of $2,594,544 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to conduct research on how mucin-degrading intestinal bacteria contribute to complications in patients undergoing allogeneic hematopoietic cell transplantation (allo HCT). The award to the Beckman Research Institute of the City of Hope will support three integrated projects over a 5-year period from September 2024 to July 2029. The projects will investigate how the gut microbiome, specifically Akkermansia and Bacteroides bacteria that can degrade intestinal mucus, impact intestinal graft-versus-host disease and neutropenic fever in allo HCT patients. The research will leverage clinical microbiome profiling, preclinical modeling, and genetic analysis of mucin-degrading enzymes to develop a better understanding of this microbial-host interaction and its implications for allo HCT complications.
Generated 3/25/25, 6:06 AM